One- and two-stage designs for stratified phase II clinical trials

Statistics in Medicine

Volumn 24, Issue 17, 2005, Pages 2597-2611

  London, Wendy B ^a   Chang, Myron N ^a  

^a University of Florida ^*  (United States)

Author keywords

Conditional test; Exact global test; Locally most powerful test; Multinomial distribution

Indexed keywords

CYCLOPHOSPHAMIDE; TOPOTECAN;

ALGORITHM; ARTICLE; BIOSTATISTICS; CANCER RELAPSE; CHILDHOOD CANCER; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; HUMAN; MATHEMATICAL COMPUTING; METHODOLOGY; NEUROBLASTOMA; PARAMETRIC TEST; PHASE 2 CLINICAL TRIAL; SAMPLE SIZE; SIMULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II; CYCLOPHOSPHAMIDE; DATA INTERPRETATION, STATISTICAL; HUMANS; INFANT; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; RESEARCH DESIGN; TOPOTECAN;

EID: 24944591389     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2139     Document Type: Article

References (6)

1. Fleming TR. One-sample multiple testing procedures for phase II clinical trials. Biometrics 1982; 38:143-151.
2. Chang MN, Therneau TM, Wieand HS, Cha SS. Designs for group sequential phase II clinical trials. Biometrics 1987; 43:865-874.
3. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10:1-10.
4. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clinical Trials 1984; 5:348-361.
5. Chang MN, Hwang IK, Shih WJ. Group sequential designs using both type I and type II error probability spending functions. Communications in Statistics, Theory and Methods 1998; 27(6):1323-1339.
6. Hintze J. NCSS and PASS Number Cruncher Statistical Systems. Kaysville, Utah. www.ncss.com, 2001.